All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Kanaph Therapeutics Inc. and Yungjin Pharmaceutical Co., Ltd. have presented tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of immunological, cardiovascular, eye disorders, fibrosis, cancer, Noonan syndrome, LEOPARD syndrome and neurofibromatosis type 1.